Fed. Circ. Backs Generic Co.'s IP Win Over Eagle Cancer Drug

By Tiffany Hu (May 8, 2020, 8:32 PM EDT) -- The Federal Circuit ruled in a precedential opinion Friday that a generic version of the cancer drug Belrapzo did not infringe patents owned by Eagle Pharmaceuticals, faulting Eagle for disclosing the alternative use of ethanol in a certain formulation without claiming it....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login